Transcutaneous Pacing Market Size, Share & Industry Analysis, By Type (Single Chamber External Pacemaker, Dual Chamber External Pacemaker, Triple Chamber External Pacemaker), By Application (Bradycardia, Tachycardia, Others), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2025-2032

Transcutaneous pacing also referred as external pacing, is recommended during a medical emergency for stabilizing irregular cardiac rhythm. In transcutaneous pacing procedure, a small electrical current is applied until normalcy is achieved or a more permanent means of pacing is achieved i.e. transvenous pacing. It is a temporary pacing technique that involves electric cardiac stimulation to treat conditions like bradycardia, and tachycardia. During transcutaneous pacing procedure, two pads or patches are placed on patient’s chest either on the anterior/posterior position or in the anterior/lateral position. Among these, the anterior/posterior position is a mostly preferred because it minimizes transthoracic electrical impedance by locating the heart between the two pads. One of the most common indication for transcutaneous pacing is symptomatic bradycardia, resulting from acute myocardial infraction and sinus node dysfunction.

Key Market Driver -

Increasing Prevalence of Cardiac Arrhythmia

Key Market Restraint -

Availability of Alternate Treatment Options

According to the data published by Biosense Webster in 2018, atrial fibrillation was the most common type of arrhythmia in Europe, affecting an estimated 11.0 million people. These trends combined with the globally increasing prevalence of bradycardia, AV blockage and tachycardia are anticipated to drive the market growth of transcutaneous pacing during the forecast period. Also, growing geriatric population with cardiac problems are also expected to boost the demand of transcutaneous pacing systems. For instance, a data published by American College of Cardiology stated that the incidence of heart failure was rising with the elderly population of the world and the major factors responsible included conditions like cardiac arrhythmias, hypertension and diabetes.

However, availability of alternate treatment options for cardiac arrhythmia like transvenous pacing, medications and implantable pacemakers, are projected to limit the adoption of transcutaneous pacing devices during the forecast period.  

Key Players Covered:

The major companies in the global transcutaneous pacing market report includes Medtronic, Biotronik, OSCOR Inc., Koninklijke Philips N.V., Galix Biomedical Instrumentation, Osypka Medical GmbH and other players.

Key Insights

• Product Mapping, By Key Players
• Prevalence of Key Cardiac Disorders, By Key Regions/Country, 2018
• Key Industry Development - Mergers and Acquisitions

Regional Analysis:

The global transcutaneous pacing market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe dominated the global transcutaneous pacing market in 2018, owing to increasing incidence of emergency cases with cardiac rhythm abnormalities, increasing expenditure on healthcare and strong distribution network of major players in these regions. According to a data published by Biosense Webster, atrial fibrillation is the most common type of arrhythmia affecting an estimated 88,600 people each year in Europe.

To gain extensive insights into the market, Download for Customization

Thus, such trends are expected to boost the adoption of transcutaneous pacing technique in Europe during the forecast period. Also, Asia Pacific is expected to witness a substantial market growth by the end of 2026 owing to the increasing incidences of cardiac arrest due to conditions like cardiac arrhythmia. Latin America and Middle East & Africa are expected to register a significant CAGR during the forecast period owing to the increasing expenditure on healthcare infrastructure.

Segmentation

Transcutaneous Pacing Industry Developments

• In January 2019, Medtronic introduced MyCareLink Heart mobile app with bluesync technology in the market that enabled pacemaker and eliminated the use of other remote monitoring device.
• In June 2018, Phillips acquired Remote Diagnostic Technologies (RDT), a UK based manufacturer of advanced solutions for monitoring, cardiac therapy and data management in order to provide a diversified product portfolio.
• In January 2017, Abbott acquired St. Jude Medical, Inc., a leader of medical devices market with an aim to strengthen its market position.